Sign in

Ilya Rachman

Chief Executive Officer (CEO) and Chairman of the Board of Directors at Immix Biopharma
Board
Since 2012
Age
53 years
Education
Holds a joint MD/PhD degree from the University of Illinois Chicago, an EMBA from the University of California at Los Angeles, and a B.S. from the University of Iowa.
Tenure
Has served as founder, Chief Executive Officer, and Chairman of the Board at IMMX since 2012.

Also at Immix Biopharma

GM
Gabriel Morris
Chief Financial Officer

About

Ilya Rachman, MD, PhD, MBA is a pioneering physician/scientist and cell biologist with extensive expertise in oncology and experimental medicine. His career began with significant contributions in clinical research, including establishing a research organization that conducted Phase 3 and 4 trials, and serving at renowned institutions such as Cedars-Sinai Medical Center and UCLA Health.

Educated at the University of Illinois Chicago, UCLA, and the University of Iowa, he has developed a strong foundation in both academic research and clinical practice. His comprehensive training in medicine and business has enabled him to bridge the gap between scientific innovation and patient care.

Since founding IMMX in 2012, he has held the roles of Founder, Chief Executive Officer, and Chairman of the Board, driving the company’s strategic initiatives in developing innovative cancer treatments. This leadership role underlines his commitment to leveraging academic research for practical, clinical breakthroughs.

$IMMX Performance Under Ilya Rachman

Past Roles

OrganizationRoleDate RangeDetails
Clinical Research Organization Founder N/A [N/A]Conducted Phase 3 and Phase 4 clinical trials for major pharmaceutical companies
Cedars-Sinai Medical Center Physician/Scientist N/A [N/A]Contributed to medical research and clinical practice
UCLA Health Physician/Scientist N/A [N/A]Participated in clinical research and trained in medicine and research

Fixed Compensation

Data from  FY 2024
Component NameAmountPayment ScheduleAdditional Details
Salary$475,000 2024 AnnualBase Salary
Option Awards$554,658 2024 Grant DateGrant date fair value of option awards
Stock Options Granted340,000 shares at $2.04/share Issued on June 11, 2024; Vest monthly over 4 years, fully vested on June 11, 2028Outstanding equity award to purchase common stock

Performance Compensation

Data from  FY 2024
Performance MetricWeight (%)Threshold/TargetEvaluation PeriodPayout DetailsAdditional Conditions
Dose patients in IMX-110 clinical trials20% Achieve set milestone2024Contributes to annual bonus payoutMilestone achieved as determined by Compensation Committee
Dose patients in NXC-201 clinical trials20% Achieve set milestone2024Contributes to annual bonus payoutMilestone achieved as determined by Compensation Committee
Complete NXC-201 technology transfer to the U.S.20% Successful transfer2024Contributes to annual bonus payoutMilestone achieved as determined by Compensation Committee
Manufacture sufficient drug supply for both programs20% Ensure adequate supply2024Contributes to annual bonus payoutMilestone achieved as determined by Compensation Committee
Complete capital raising and hiring activities20% Secure capital and hire2024Contributes to annual bonus payoutMilestone achieved as determined by Compensation Committee
Performance Bonus (Cash)N/A50% of Base Salary2024$237,500 cash bonus awarded upon achievement of all milestonesPaid as cash bonus; no vesting applicable